Progress in the discovery of naturally occurring anti-diabetic drugs and in the identification of their molecular targets

Fitoterapia

Volumn 134, Issue , 2019, Pages 270-289

  He, Jian Hua ^a   Chen, Li Xia ^a   Li, Hua ^a,b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Molecular targets; Natural occurring drugs; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALPHA GLUCOSIDASE; AMYLASE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; NATURAL PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTOCHEMICAL; PLANT EXTRACT; PROTEIN TYROSINE PHOSPHATASE 1B; BIOLOGICAL PRODUCT;

ANTIDIABETIC ACTIVITY; DIABETES MELLITUS; DRUG TARGETING; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; ISOLATION AND PURIFICATION; MOLECULARLY TARGETED THERAPY;

BIOLOGICAL PRODUCTS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY;

EID: 85062472842     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2019.02.033     Document Type: Review

References (287)

1. Vlad, I., Popa, A.R., Epidemiology of diabetes mellitus: a current review. Rom. J. Diabetes Nutr. Metab. Diseas. 19 (2016), 433–440.
2. International Diabetic Federation (IDF) (2016) IDF Diabetic Atlas, 7th ed. http://www.vision2020uk.org.uk/idf-diabetes-atlas-7th-edition.
3. Park, J., Jang, H.J., Anti-diabetic effects of natural products an overview of therapeutic strategies. Mol. Cell. Toxicol. 13 (2017), 1–20.
4. Blonde, L., Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve. Clin. J. Med. 76:5 (2009), S4–S11.
5. Distefano, J.K., Watanabe, R.M., Pharmacogenetics of antidiabetes drugs. Pharmaceuticals (Basel) 3 (2010), 2610–2646.
6. Tahrani, A.A., Bailey, C.J., Del Prato, S., Barnett, A.H., Management of type 2 diabetes: new and future developments in treatment. Lancet 378 (2011), 182–197.
7. Bennett, W.L., Wilson, L.M., Bolen, S., et al. Oral diabetes medications for adults with type 2 diabetes: an update [Internet]. Agen. Healthc. Res. Qual., 233, 2011.
8. Thulé Peter M., Mechanisms of current therapies for diabetes mellitus type 2. Adv. Physiol. Educ. 36 (2012), 275–283.
9. Dan, J., Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat. Rev. Drug Discov., 10, 2011, 645.
10. Rucker, D.J., The biology of incretin hormones. Cell Metab. 3 (2006), 153–165.
11. Drucker, D.J., et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33 (2010), 428–433.
12. Xu, L., Li, Y., Dai, Y., Peng, J., Natural products for the treatment of type 2 diabetes mellitus: pharmacology and mechanisms. Pharmacol. Res. 130 (2018), 451–465.
13. Jung, M., Park, M., Lee, H.C., Kang, Y.H., Kim, S.K., Antidiabetic agents from medicinal plants. Curr. Med. Chem. 13 (2006), 1203–1218.
14. Bailey, C.J., Day, C., Metformin: its botanical background. Pract. Diabetes Int 21 (2004), 115–117.
15. Peijun, Z., Badrul, A.M., Seok-Hyun, L., Young-Jun, K., Seul, L., Hongyan, A., et al. Spatholobus suberectus\r, exhibits antidiabetic activity in vitro and in vivo through activation of akt-ampk pathway. Evid. Based Complement. Alternat. Med., 2017, 1–12.
16. Hung, H.Y., Qian, K., Morris-Natschke, S.L., Hsu, C.S., Lee, K.H., Recent discovery of plant-derived anti-diabetic natural products. Nat. Prod. Rep., 29, 2012, 580.
17. Procacci, V., Giovine, A., Roberto, M.G., Di, R.N., Lasorsa, G., Vendemiale, G., et al. Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus. Boll. Soc. Ital. Biol. Sper. 64 (1988), 817–824.
18. Kreisberg, R.A., The second-generation sulfonylureas: change orprogress?. Ann. Intern. Med. 102 (1985), 125–126.
19. Burge, M.R., Schmitz-Fiorentino, K., Fischette, C., Qualls, C.R., Schade, D.S., A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 279 (1998), 137–143.
20. Franco, R.R., Da, S.C.D., Fbr, D.M., Justino, A.B., Guerra Silva, H.C., Peixoto, L.G., et al. Evaluation of α-amylase, α-glucosidase and lipase inhibitory activities of some medicinal plants used in type-2 diabetes mellitus and its anti-glycation and antioxidant roles. J. Ethnopharmacol., 215, 2017.
21. Bray, G.A., Greenway, F.L., Weight-Loss Drugs. 2007, Humana Press, 341–368.
22. Vicente-Pedrós, F., Trejueque, M.J., Tomás, V.F., Antidiabetic behavior of biguanides. J. Pharm. Sci. 72 (1983), 565–567.
23. Berger, W., Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. Horm. Metab. Res. Suppl. 15 (1985), 111–115.
24. Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Lerch, C., Dipeptidyl peptidase-4 (dpp-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 16, 2008, CD006739.
25. Röhrborn, D., Wronkowitz, N., Eckel, J., DPP4 in diabetes. Front. Immunol., 6, 2015, 386.
26. Saltiel, A.R., Olefsky, J.M., Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45 (1996), 1661–1669.
27. King, A.B., A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care, 23, 2000, 557.
28. Pratley, R.E., Gilbert, M., Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev. Diabet. Stud. 5 (2008), 73–94.
29. Filippatos, T.D., Panagiotopoulou, T.V., Elisaf, M.S., Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud. 11 (2014), 202–230.
30. Clar, C., Gill, J.A., Court, R., Waugh, N., Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2 (2012), 1–7.
31. Halimi, S., Vergès, B., Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 40 (2014), S28–S34.
32. Morris, A.P., Voight, B.F., Teslovich, T.M., et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44 (2012), 981–990.
33. Scott, R.A., Lagou, V., Welch, R.P., Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat. Genet. 44 (2012), 991–1005.
34. Gray, G.M., Carbohydrate digestion and absorption. Role of the small intestine. N. Engl. J. Med. 292 (1975), 1225–1230.
35. Liu, D., Gao, H., Tang, W., Nie, S., Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 1401 (2017), 28–36.
36. Wani, J.H., John-Kalarickal, J., Fonseca, V.A., Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol. Clin. 26 (2008), 639–648.
37. Stenbit, A.E., Tsao, T.S., Li, J., Burcelin, R., Geenen, D.L., Factor, S.M., et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat. Med., 3, 1997, 1096.
38. Kishi, K., Muromoto, N., Nakaya, Y., Miyata, I., Hagi, A., Hayashi, H., et al. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 47 (1998), 550–558.
39. Rea, S., James, D.E., Moving GLUT4: the biogenesis and trafficking of GLUT4 storage vesicles. Diabetes 46 (1997), 1667–1677.
40. Evans, J.L., Jallal, B., Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Expert Opin. Investig. Drugs, 8, 1999, 139.
41. Seely, B.L., Staubs, P.A., Reichart, D.R., Berhanu, P., Milarski, K.L., Saltiel, A.R., et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes, 45, 1996, 1379.
42. Johnson, T.O., Ermolieff, J., Jirousek, M.R., Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. 1 (2002), 696–709.
43. Li, X., Hansen, P.A., Xi, L., Chandraratna, R.A., Burant, C.F., Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid x receptors. J. Biol. Chem. 280 (2005), 38317–38327.
44. Kramer, D., Shapiro, R., Adler, A., Bush, E., Rondinone, C.M., Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 50 (2001), 1294–1300.
45. Cabrero, A., Laguna, J.C., Vazquez, M., Peroxisome proliferator-activated receptors and the control of inflammation. Curr. Drug Targets Inflamm. Allergy 1 (2002), 243–248.
46. Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., Matsuzawa, Y., PPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001), 2094–2099.
47. Baker, R.G., Hayden, M.S., Ghosh, S., NF-κB, inflammation, and metabolic disease. Cell Metab. 13 (2011), 11–22.
48. Crunkhorn, Sarah, Metabolic disorders: breaking the links between inflammation and diabetes. Nat. Rev. Drug Discov., 12, 2013, 261.
49. Sivapragasam, G., Palanivel, G., Park, S.Y., Natural phyto-bioactive compounds for the treatment of type 2 diabetes: inflammation as a target. Nutrients, 8, 2016, 461.
50. Sears, B., Ricordi, C., Anti-inflammatory nutrition as a pharmacological approach to treat obesity. J. Obes. 2011 (2010), 130–136.
51. Chen, L., Chen, R., Wang, H., Liang, F., Mechanisms linking inflammation to insulin resistance. Int. J. Endocrinol., 2015, 2015, 508409.
52. Collier, A., Wilson, R., Bradley, H., Thomson, J.A., Free radical activity is type 2 diabetes. Diabetes Med. 7 (1990), 27–30.
53. Baynes, J.W., Thorpe, S.R., Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 (1999), 1–9.
54. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature. 414 (2001), 813–820.
55. Mohazzab, K.M., Kaminski, P.M., Wolin, M.S., NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am. J. Physiol., 266, 1994, H2568.
56. Evans, J.L., Goldfine, I.D., Maddux, B.A., Grodsky, G.M., Oxidative stress and stress-activated signalling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23 (2002), 599–622.
57. Ling, C., Groop, L., Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58 (2009), 2718–2725.
58. Keatin, S., El-Osta, A., Epigenetic changes in diabetes. Clin. Genet. 84 (2013), 1–10.
59. Sundsten, T., Ortsäter, H., Proteomics in diabetes research. Mol. Cell. Endocrinol. 297 (2009), 93–103.
60. Mueller, P.W., Technologies for diabetes genomics. J. Diabetes Sci. Technol. 3 (2009), 735–738.
61. Floyd, J.S., Psaty, B.M., The application of genomics in diabetes: barriers to discovery and implementation. Diabetes Care 39 (2016), 1858–1869.
62. Jenkinson, C.P., Göring, Harald H.H., Arya, R., Blangero, J., Duggirala, R., Defronzo, R.A., Transcriptomics in type 2 diabetes: bridging the gap between genotype and phenotype. Genomics Data. 8 (2016), 25–36.
63. Herder, C., Roden, M., Carstensen, M., Prokisch, H., Transcriptomics und type 2 diabetes. Diabetologe 8 (2012), 35–41.
64. Wang, L., Waltenberger, B., Pferschy-Wenzig, E.M., Blunder, M., Liu, X., Malainer, C., et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR γ): a review. Biochem. Pharmacol. 92 (2014), 73–89.
65. Thareja, S., Aggarwal, S., Bhardwaj, T.R., Kumar, M., Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus. Med. Res. Rev. 32 (2012), 459–517.
66. Zhou, J., Chan, L., Zhou, S., Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr. Med. Chem. 19 (2012), 3523–3531.
67. Khan, H., Khattak, S., Phyto-glycosides as therapeutic target in the treatment of diabetes. Mini Rev. Med. Chem., 16, 2016, 999.
68. Anhê F.F., Desjardins, Y., Pilon, G., Dudonné S., Genovese, M.I., Lajolo, F.M., Polyphenols and type 2 diabetes: a prospective review. Pharmanutrition. 1 (2013), 105–114.
69. Sayahi, M., Shirali, S., The antidiabetic and antioxidant effects of carotenoids: a review. Asian J. Pharm. Res. Health Care 9 (2017), 186–191.
70. Rao, M.U., Sreenivasulu, M., Chengaiah, B., Reddy, K.J., Chetty, C.M., Herbal medicines for diabetes mellitus: a review. Int. J. Pharm. Res. 2 (2010), 1883–1892.
71. Vinayagam, R., Xu, B., Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr. Metab. 12 (2015), 1–20.
72. Gowd, V., Jia, Z., Chen, W., Anthocyanins as promising molecules and dietary bioactive components against diabetes – a review of recent advances. Trends Food Sci. Technol. 68 (2017), 1–13.
73. Ponnaiya, V., Tamizhamuthu, M., Dhivya, M., Fathima, A.S.N., Merish, S., Chandran, G.S., Effect of Tocopherol, Polyphenols in the Management of Diabetes and its Complications-Appraisal. International Seminar on Dia-Fest, 2014.
74. Qiu, J.G., Chang, T.H., Steinberg, J.J., Levenson, S.M., Single local instillation of Staphylococcus aureus peptidoglycan prevents diabetes-induced impaired wound healing. Wound Repair Regen. 6 (2010), 449–456.
75. Waterbrook, A.L., Balcik, B.J., Goshinska, A.J., Blood glucose levels after local musculoskeletal steroid injections in patients with diabetes mellitus: a clinical review. Sports Health. 9 (2017), 372–374.
76. Elekofehinti, O.O., Saponins: anti-diabetic principles from medicinal plants: a review. Pathophysiology. 22 (2015), 95–103.
77. Nguyen, C.N., Trinh, Binh T., Tran, Toan B., Nguyen, Le-Thu T., Jäger, Anna K., Nguyen, Lien-Hoa D., Anti-diabetic xanthones from the bark of Garcinia xanthochymus. Bioorg. Med. Chem. Lett. 27 (2017), 3301–3304.
78. Wu, J., Shi, S., Wang, H., Wang, S., Mechanisms underlying the effect of polysaccharides in the treatment of type 2 diabetes: a review. Carbohydr. Polym. 144 (2016), 474–494.
79. Ortíz-Martinez, David Mizael, Catalina, R.M., Angelica, G.R.M., Julia, V.S.M., Adriana, N.G.M., Catalina, L.R., Miconia, sp. increases mRNA levels of PPAR gamma and inhibits alpha amylase and alpha glucosidase. Evid. Based Complement. Alternat. Med., 2016, 1–6.
80. Lotulung, P.D.N., Mozef, T., Risdian, C., Darmawan, A., In vitro antidiabetic activities of extract and isolated flavonoid compounds from Artocarpus altilis (parkinson) fosberg. Indian J. Chem. 14 (2014), 7–11.
81. Lee, C.W., Han, J.S., Hypoglycemic effect of Sargassum ringgoldianum extract in stz-induced diabetic mice. Prev. Nutr. Food Sci. 17 (2012), 8–13.
82. Park, M.H., Ju, J.W., Park, M.J., Han, J.S., Daidzein inhibits carbohydrate digestive enzymes in vitro and alleviates postprandial hyperglycemia in diabetic mice. Eur. J. Pharmacol. 712 (2013), 48–52.
83. Kim, A.R., Jeong, S.M., Kang, M.J., Jang, Y.H., Choi, H.N., Kim, J.I., Lotus leaf alleviates hyperglycemia and dyslipidemia in animal model of diabetes mellitus. Nutr. Res. Pract. 7 (2013), 166–171.
84. Park, M.H., Han, J.S., Hypoglycemic effect of padina arborescens extract in streptozotocin-induced diabetic mice. Prev. Nutr. Food Sci. 17 (2012), 239–244.
85. Moradabadi, L., Montasser Kouhsari, S., Fehresti Sani, M., Hypoglycemic effects of three medicinal plants in experimental diabetes: inhibition of rat intestinal α-glucosidase and enhanced pancreatic insulin and cardiac glut-4 mRNAs expression. Iran J Pharm Res. 12 (2013), 387–397.
86. Zargari, A., Medicinal Plant. 1997, Tehran University Press, Iran, 59–64.
87. Alarcon-Aguila, F.J., Roman-Ramos, R., Flores Saenz, J.L., Aguirre-Garcia, F., Investigation on the hypoglycaemic effects of extracts of four Mexican medicinal plants in normal and alloxan-diabetic mice. Phytother. Res. 16 (2002), 383–386.
88. Naghibi, F., Mosaddegh, M., Mohammadi Motamed, S., Ghorbani, A., Labiatae family in folk medicine in Iran: from Ethnobotany to Pharmacology. Iran. J. Pharm. Res. 2 (2005), 63–79.
89. Kar, A., Choudhary, B.K., Bandyopadhyay, N.G., Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. J. Ethnopharmacol. 84 (2003), 105–108.
90. Matsuura, H., Asakawa, C., Kurimoto, M., Mizutani, J., α-glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa. Biosci. Biotech. Biochem. 66 (2002), 1576–1578.
91. Uebanso, T., Arai, H., Taketani, Y., Fukaya, M., Yamamoto, H., Mizuno, A., et al. Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J. Nutr. Sci. Vitaminol. 53 (2007), 482–488.
92. Nhiem, N.X., Kiem, P.V., Minh, C.V., Ban, N.K., Cuong, N.X., Tung, N.H., et al. α-glucosidase inhibition properties of cucurbitane-type triterpene glycosides from the fruits of Momordica charantia. Chem. Pharm. Bull. 58 (2010), 720–724.
93. Sundar, P., Madasamy, P., In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantial). BMC Complement. Altern. Med., 16, 2016, 185.
94. Liggins, J., Mulligan, A., Runswick, S., Bingham, S.A., Daidzein and genistein content of cereals. Eur. J. Clin. Nutr. 56 (2002), 961–966.
95. Park, S.A., Choi, M.S., Cho, S.Y., Seo, J.S., Jung, U.J., Kim, M.J., et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in c57bl/ksj-db/db mice. Life Sci. 79 (2006), 1207–1213.
96. Riya, M.P., Antu, K.A., Pal, S., Chandrakanth, K.C., Anilkumar, K.S., Tamrakar, A.K., et al. Antidiabetic property of Aerva lanata (L.) Juss. ex Schult. is mediated by inhibition of alpha glucosidase, protein glycation and stimulation of adipogenesis. J. Diabetes 7 (2015), 548–561.
97. Spinola, V., Castilho, P.C., Evaluation of Asteraceae herbal extracts in the management of diabetes and obesity. contribution of caffeoylquinic acids on the inhibition of digestive enzymes activity and formation of advanced glycation end-products (in vitro). Phytochemistry. 143 (2017), 29–35.
98. Singh, B., Kaur, A., Antidiabetic potential of a peptide isolated from an endophytic Aspergillus awamori. J. Appl. Microbiol. 120 (2016), 301–311.
99. Dong, J., Cai, F., Shen, R., Liu, Y., Hypoglycaemic effects and inhibitory effect on intestinal disaccharidases of oat beta-glucan in streptozotocin-induced diabetic mice. Food Chem. 129 (2011), 1066–1071.
100. Huang, D., Jiang, Y., Chen, W., Yao, F., Huang, G., Sun, L., Evaluation of hypoglycemic effects of polyphenols and extracts from Penthorum chinense. J. Ethnopharmacol. 163 (2015), 256–263.
101. Wang, Z.Q., Seunghwan, H., Sunyoub, L., Soonsung, L., Fermentation of purple jerusalem artichoke extract to improve the α-glucosidase inhibitory effect in vitro and ameliorate blood glucose in db/db mice. Nutr. Res. Pract. 10 (2016), 282–287.
102. Toshio, M., Junji, A., Kiyofumi, N., Eri, K., Genzoh, T., Yutana, P., et al. Salacinol and related analogs: new leads for type 2 diabetes therapeutic candidates from the thai traditional natural medicine Salacia chinensis. Nutrients. 7 (2015), 1480–1493.
103. Zheng, H.H., Luo, C.T., Chen, H., Lin, J.N., Ye, C.L., Mao, S.S., et al. Xanthones from Swertia mussotii as multitarget-directed antidiabetic agents. Chemmedchem. 9 (2014), 1374–1377.
104. Jo, S.H., Cho, C.Y., Lee, J.Y., Ha, K.S., Kwon, Y.I., Apostolidis, E., In vitro and in vivo reduction of postprandial blood glucose levels by ethyl alcohol and water zingiber mioga, extracts through the inhibition of carbohydrate hydrolyzing enzymes. BMC Complement. Altern. Med., 16, 2016, 111.
105. Kshirsagar, A.D., Aggarwal, A.S., Harle, U.N., et al. DPP IV inhibitors: ssuccesses, failures and future prospects. Diabetes Metab. Syndr. 5 (2011), 105–112.
106. Wang, X., Li, Y., Gui, X.R., et al. Progress in dipeptidyl peptidase-4 and its inhibitors. Chin. Pharm. J. 48 (2013), 1789–1796.
107. Gurudeeban, S., Satyavani, K., Ramanathan, T., et al. Dipeptidyl peptidase IV inhibitors derived from a mangrove flora Rhizophora mucronata: an in silico approach. Bangladesh J. Pharmacol. 7 (2012), 203–210.
108. Mentlein, R., Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85 (1999), 9–24.
109. Holst, J.J., VilsbØll, T., Deacon, C.F., The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297 (2009), 127–136.
110. Deacon, C.F., Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 36 (2004), 761–765.
111. Gao, Y., Zhang, Y., Zhu, J., Li, B., Li, Z., Zhu, W., Shi, J., Jia, Q., Li, Y., Recent progress in natural products as DPP-4 inhibitors. Future Med. Chem., 7, 2015, 1079.
112. DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study. Diabetes Res. Clin. Pract., 97, 2012.
113. Ayachi, Hicham, Merad, Meriem, Ghalem, Said, Study of interaction between dipeptidyl peptidase-4 and products extracted from the Stevia plant by molecular modeling. Int. J. Pharm. Sci. Rev. Res. 23 (2013), 87–90.
114. Huang, C.N., Wang, C.J., Lee, Y.J., Peng, C.H., Active subfractions of Abelmoschus esculentus substantially prevent free fatty acid-induced β cell apoptosis via inhibiting dipeptidyl peptidase-4. PLoS One, 12, 2017, e0180285.
115. Zhang, L., Zhang, S.T., Yin, Y.C., Xing, S., Li, W.N., Fu, X.Q., Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic mice. RSC Adv. 8 (2018), 14967–14974.
116. Sulaiman, A.A., Effect of single oral dose of proanthocyanidin on postprandial hyperglycemia in healthy rats: a comparative study with sitagliptin. J. Intercult. Ethnopharmacol. 3 (2014), 73–77.
117. Ahrén, B., Landin-Olsson, M., Jansson, P.A., Svensson, M., Holmes, D., Schweizer, A., Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004), 2078–2084.
118. Bhartia, S.K., Kumar, A., Rajak, K.K., Murari, K., Bharti, B.K., Gupta, A.K., Antihyperglycemic activity with DPP-4 inhibition of alkaloids from seed extract of Castanospermum australe: investigation by experimental validation and molecular docking. Phytomedicine. 20 (2012), 24–31.
119. Jones, G., Willett, P., Glen, R.C., Leach, A.R., Taylor, R., Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997), 727–748.
120. Yang, M.K., Tang, Y.S., Cai, L.M., Xie, J.X., Shen, F.C., Lin, X.Y., et al. the isolation and structure of argutone–a new bacteriostatic constituent of Incarvillea arguta. Yao Xue Xue Bao 22 (1987), 711–715.
121. Leng, S.H., Lu, F.E., Xu, L.J., Therapeutic effects of berberine in impaired glucose tolerance rat and its influence on insulin secretion. Acta Pharmacol. Sin. 25 (2004), 496–502.
122. Al-Masri, I.M., Mohammad, M.K., Tahaa, M.O., Inhibition of dipeptidyl peptidase 4 (DPP-4) is one of the mechanisms explaining the hypoglycemic effect of berberine. J. Enzym. Inhib. Med. Chem., 24, 2009, 1061.
123. Estrada-Salas, P.A., Monetero-Morán, Gabriela M., Martínez-Cuevas, Pedro P., González, Carmen, Barba, P., Characterization of antidiabetic and antihypertensive properties of canary seed (Phalaris canariensis L.) peptides. J. Agric. Food Chem. 62 (2014), 427–433.
124. Geng, Y., Lu, Z.M., Huang, W., Xu, H.Y., Shi, J.S., Xu, Z.H., Bioassay-guided isolation of DPP-4 inhibitory fractions from extracts of submerged cultured of Inonotus obliquus. Molecules 18 (2013), 1150–1161.
125. Tadashi, H., Yosikazu, I., Jiro, A., Yuya, K., Hirokazu, U., Kayoko, K., et al. Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food Chem. 134 (2012), 797–802.
126. Ji, W., Zhang, C., Ji, H., Purification, identification and molecular mechanism of two dipeptidyl peptidase IV (DPP IV) inhibitory peptides from antarctic krill (Euphausia superba) protein hydrolysate. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 1064, 2017, 56.
127. Velarde-Salcedo, Aída J., Barrera-Pacheco, A., Lara-González, Samuel, Montero-Morán, Gabriela M., Díaz-Gois, Agustín, de Mejia, Elvira González, et al. In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins. Food Chem. 136 (2013), 758–764.
128. Huang, S.L., Jao, C.L., Ho, K.P., Hsu, K.C., Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides. 35 (2012), 114–121.
129. Bower, A.M., Hernandez, L.M.R., Berhow, M.A., Mejia, E.G.D., Bioactive compounds from culinary herbs inhibit a molecular target for type-2 diabetes management, dipeptidyl peptidase IV. J. Agric. Food Chem., 62, 2014, 6147.
130. Cazzola, R., Camerotto, C., Cestaro, B., Anti-oxidant, anti-glycant, and inhibitory activity against α-amylase and α-glucosidase of selected spices and culinary herbs. Int. J. Food Sci. Nutr. 62 (2011), 175–184.
131. Koga, K., Shibata, H., Yoshino, K., Nomoto, K., Effects of 50% ethanol extract from rosemary (Rosmarinus officinalis) on α-glucosidase inhibitory activity and the elevation of plasma glucose level in rats, and its active compound. J. Food Sci. 71 (2006), S507–S512.
132. Ibarra, A., Cases, J., Roller, M., Chiralt-Boix, A., Coussaert, A., Ripoll, C., Carnosic acid-rich rosemary (Rosmarinus officinalis L.) leaf extract limits weight gain and improves cholesterol levels and glycaemia in mice on a high-fat diet. Br. J. Nutr. 106 (2011), 1182–1189.
133. Mueller, M., Lukas, B., Novak, J., Simoncini, T., Genazzani, A.R., Jungbauer, A., Oregano: a source for peroxisome proliferatoractivated receptor gamma antagonists. J. Agric. Food Chem. 56 (2008), 11621–11630.
134. Abdel-Aal, E.S.M., Hucl, P.J., Sosulski, F.W., Structural and compositional characteristics of canary seed (Phalaris canariensis L.). J. Agric. Food Chem. 45 (1997), 3049–3055.
135. Bansal, P., Paul, S.P., Pannakal, S.T., Mudgal, J., Priyadarsini, K., Unnikrishnan, M., et al. Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fatdiet/streptozotocin-induced diabetes in mice. Exp. Toxicol. Pathol. 64 (2012), 651–658.
136. Noemi Lang, G.J., Shang, J.Y., Chen, Y.X., Cui, Y.J., Wang, Q., Tang, Z.H., et al. Molecular basis of selective PPAR γ modulation for the treatment of type 2 diabetes. Biochim. Biophys. Acta 1771 (2007), 1094–1107.
137. Murphy, G.J., Holder, J.C., PPAR γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 21 (2000), 469–474.
138. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Eng. J. Med. 356 (2007), 2457–2471.
139. Singh, S., Loke, Y.K., Furberg, C.D., Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007), 1189–1195.
140. Home, P.D., Pocock, S.J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N. Eng. J. Med. 357 (2007), 28–38.
141. Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, openlabel trial. Lancet. 373 (2009), 2125–2135.
142. Nissen, S.E., Wolski, K., Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortsality. Arch. Intern. Med. 170 (2010), 1191–1201.
143. Atanasov, A.G., Wang, J.N., Gu, S.P., Bu, J., Kramer, M.P., Baumgartner, L., et al. Honokiol: a non-adipogenic PPAR γ agonist from nature. Biochim. Biophys. Acta 1830 (2013), 4813–4819.
144. Zhang, H., Xu, X., Chen, L., Chen, J., Hu, L., Jiang, H., Shen, X., Molecular determinants of magnolol targeting both RXR α and PPAR γ. PLoS One, 6, 2011, e28253.
145. Kotani, H., Tanabe, H., Mizukami, H., Makishima, M., Inoue, M., Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J. Nat. Prod. 73 (2010), 1332–1336.
146. Lee, S.Y., Park, S.L., Hwang, J.T., Yi, S.H., Nam, Y.D., Lim, S.I., Antidiabetic effect of Morinda citrifolia (Noni) fermented by cheonggukjang in KK-Ay diabetic mice. Evid. Based Complement. Alternat. Med., 163280, 2012.
147. Kim, S.H., Hur, H.J., Yang, H.J., Kim, H.J., Kim, M.J., Park, J.H., et al. Citrus junos tanaka peel extract exerts antidiabetic effects via AMPK and PPAR- ?? both in vitro and in vivo in mice fed a high-fat diet. Evid. Based Complement. Alternat. Med., 16, 2013, 921012.
148. Hahm, S.W., Park, J., Son, Y.S., Opuntia humifusa stems lower blood glucose and cholesterol levels in streptozotocin-induced diabetic rats. Nutr. Res. 31 (2011), 479–487.
149. Okusada, K., Nakamoto, K., Nishida, M., Wakako, F.H., Kamiya, K., Mizushina, Y., et al. The antinociceptive and anti-inflammatory action of the chcl3-soluble phase and its main active component, damnacanthal, isolated from the root of morinda citrifolia. Biol. Pharm. Bull. 34 (2011), 103–107.
150. Su, B.N., Pawlus, A.D., Jung, H.A., Keller, W.J., Mclaughlin, J.L., Kinghorn, A.D., Chemical constituents of the fruits of Morinda citrifolia (noni) and their antioxidant activity. J. Nat. Prod. 68 (2005), 592–595.
151. Yoo, K.M., Lee, K.W., Park, J.B., Lee, H.J., Hwang, I.K., Variation in major antioxidants and total antioxidant activity of yuzu (Citrus junus Sieb ex Tanaka) during maturation and between cultivars. J. Agric. Food Chem. 52 (2004), 5907–5913.
152. Hirota, R., Roger, N.N., Nakamura, H., Song, H.S., Sawamura, M., Suganuma, N., Anti-inflammatory effects of limonene from yuzu (Citrus junos Tanaka) essential oil on eosinophils. J. Food Sci. 75 (2010), H87–H92.
153. Cho, J.Y., Park, S.C., Kim, T.W., Kim, K.S., Song, J.C., Kim, S.K., Lee, H.M., Sung, H.J., Park, H.J., Song, Y.B., Yoo, E.S., Lee, C.H., Rhee, M.H., Radical scavenging and anti-inflammatory activity of extracts from Opuntia humifusa Raf. J. Pharm. Pharmacol. 58 (2006), 113–119.
154. Zheng, W., Qiu, L., Wang, R., Feng, X., Han, Y., Zhu, Y., et al. Selective targeting of PPAR γ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency. Sci. Rep., 5, 2015, 12222.
155. Atanasov, A.G., Blunder, M., Fakhrudin, N., Liu, X., Noha, S.M., Malainer, C., Schinkovitz, A., Heiss, E.H., Schuster, D., Dirsch, V.M., Bauer, R., Polyacetylenes from Notopterygium incisum new selective partial agonists of peroxisome proliferator-activated receptor-gamma. Plos One, 8, 2013, e61755.
156. Zhou, Y., Wu, Y., Qin, Y., Liu, L., Mi, M., et al. Ampelopsin improves insulin resistance by activating PPAR γ and subsequently up-regulating FGF21-AMPK signaling pathway. PLoS One, 11, 2016, e0159191.
157. Weidner, C., De Groot, J.C., Prasad, A., Freiwald, A., Quedenau, C., Kliem, M., et al. Amorfrutins are potent antidiabetic dietary natural products. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 7257–7262.
158. Zhu, C., Zhang, W., Mu, B., Zhang, F., Lai, N., Zhou, J., et al. Effects of marine collagen peptides on glucose metabolism and insulin resistance in type 2 diabetic rats. J. Food Sci. Technol. 54 (2017), 1–10.
159. Park, H.G., Bak, E.J., Woo, G.H., Kim, J.M., Quan, Z., Kim, J.M., et al. Licochalcone E has an antidiabetic effect. J. Nutr. Biochem., 23, 2012.
160. Yang, M.H., Vasquez, Y., Ali, Z., Khan, I.A., Khan, S.I., Constituents from terminalia species increase PPAR α and PPAR γ levels and stimulate glucose uptake without enhancing adipocyte differentiation. J. Ethnopharmacol. 149 (2013), 490–498.
161. Yang, X., Huang, M., Yang, J., Wang, J., Zheng, S., Ma, X., et al. Activity of isoliensinine in improving the symptoms of type 2 diabetic mice via activation of amp-activated kinase and regulation of PPAR γ. J. Agric. Food Chem., 65, 2017.
162. Oowatari, Y., Ogawa, T., Katsube, T., Iinuma, K., Yoshitomi, H., Gao, M., Wasabi leaf extracts attenuate adipocyte hypertrophy through PPAR γ and AMPK. J. Agric. Chem. Soc. Jpn., 80, 2016, 8.
163. Le, H.T., Ponniah, S., Pallen, C.J., Insulin signaling and glucose homeostasis in mice lacking protein tyrosine phosphatase α. Biochem. Biophys. Res. Commun. 314 (2004), 321–329.
164. Rocchi, S., Tartare-Deckert, S., Sawka-Verhelle, D., Gamha, A., van Obberghen, E., Interaction of SH2-containing protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system. Endocrinol 137 (1996), 4944–4952.
165. Tenev, T., Keilhack, H., Tomic, S., Stoyanov, B., Stein-Gerlach, M., Lammers, R., Krivtsov, A.V., Ullrich, A., Bohmer, F.D., Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2 chimera. J. Biol. Chem. 272 (1997), 5966–5973.
166. Thiyagarajan, G., Muthukumaran, P., Kumar, B.S., Muthusamy, V.S., Lakshmi, B.S., Selective inhibition of ptp1b by vitalboside a from Syzygium cumini enhances insulin sensitivity and attenuates lipid accumulation via partial agonism to PPAR γ : in vitro and in silico investigation. Chem. Biol. Drug Des. 88 (2016), 302–312.
167. Sun, W., Zhang, B., Zheng, H., Zhuang, C., Li, X., Lu, X., et al. Trivaric acid, a new inhibitor of PTP1B with potent beneficial effect on diabetes. Life Sci., 169, 2016, 52.
168. Wang, Z.L., Han, S.Y., Chu, J.X., The effects of total flavonoids from buckwheat flowers and leaves on renal damage and PTP1B expression in type 2 diabetic rats. Iran. J. Pharm. Res., 10, 2011, 511.
169. Davis, J.A., Sharma, S., Mittra, S., Sujatha, S., Kanaujia, A., Shukla, G., et al. Antihyperglycemic effect of Annona squamosa hexane extract in type 2 diabetes animal model: PTP1B inhibition, a possible mechanism of action?. Indian J. Pharm. 44 (2012), 326–332.
170. Marrero-Faz, E., Sanchez-Calero, J., Young, L., Harvey, A., Inhibitory effect of Persea americana Mill leaf aqueous extract and its fractions on PTP1B as therapeutic target for type 2 diabetes. Bol Latinoam Caribe Plant Med Aromat. 13 (2014), 144–151.
171. Lima, C.R., Vasconcelos, C.F.B., Costa-Silva, J.H., Maranhão, C.A., Costa, J., Batista, T.M., et al. Anti-diabetic activity of extract from Persea americana Mill. leaf via the activation of protein kinase B (PKB/Akt) in streptozotocin induced diabetic rats. J. Ethnopharmacol. 141 (2012), 517–525.
172. Mahadeva, R., Adinew, B., Remnant B-cellstimulative and anti-oxidative effects of Persea americana fruit extract studied in rats introduced into streptozotocin induced hyperglycaemic state. Afric J Trad Compl Altern Med. 8 (2011), 210–217.
173. Yasir, M., Sattwik, D., Kharya, M.D., The phytochemical and pharmacological profile of Persea americana Mill. Pharmacogn. Rev. 4 (2010), 77–84.
174. Wezel, A., Bender, S., Plant species diversity of homegardens of cuba and its significance for household food supply. Agrofor. Syst. 57 (2003), 39–49.
175. Kim, Dae Hoon, Lee, Sooung, Chung, Youn Wook, Kim, Byeong Mo, Kim, Hanseul, Kim, Kunhong, Yang, Kyung Mi, Antiobesity and antidiabetes effects of a Cudrania tricuspidata hydrophilic extract presenting PTP1B inhibitory potential. Biomed. Res. Int. 2016 (2016), 1–11.
176. Uddin, Z., Song, Y.H., Ullah, M., Li, Z., Kim, J.Y., Park, K.H., Isolation and characterization of protein tyrosine phosphatase 1b (ptp1b) inhibitory polyphenolic compounds from Dodonaea viscosaand their kinetic analysis. Front. Chem., 6, 2018, 40.
177. Owolabi, M.A., Jaja, S.I., Coker, H.A.B., Vasorelaxant action of aqueous extract of the leaves of Persea americana, on isolated thoracic rat aorta. Fitoterapia. 76 (2005), 567–573.
178. Yong, Z., Chen, M.X., Kongstad, K.T., Jager, A.K., Dan, S., The potential of Polygonum cuspidatum root as an antidiabetic food-dual high-resolution α-glucosidase and ptp1b inhibition profiling combined with hplc-hrms and nmr for identification of antidiabetic constituents. J. Agric. Food Chem. 65 (2017), 4421–4427.
179. Sohn, E., Kim, J., Kim, C.S., Jo, K., Lee, Y.M., Kim, J.S., Root of Polygonum cuspidatum extract reduces progression of diabetes induced mesangial cell dysfunction via inhibition of platelet-derived growth factor-BB (PDGF-BB) and interaction with its receptor in streptozotocin-induced diabetic rats. BMC Complement. Altern. Med., 14, 2014, 477.
180. Sohn, E., Kim, J., Kim, C.S., Jo, K., Lee, Y.M., Kim, J.S., Extract of Polygonum cuspidatum attenuates diabetic retinopathy by inhibiting the high-mobility group box-1 (HMBG1) signalling pathway in streptozotocin-induced diabetic rats. Nutrients., 8, 2016, 140.
181. Sasaki, T., Li, W., Higai, K., Quang, T., Kim, Y., Koike, K., Protein tyrosine phosphatase 1b inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens. Planta Med. 80 (2014), 557–560.
182. Govers, R., Molecular mechanisms of GLUT4 regulation in adipocytes. Diabetes Metab. 40 (2014), 400–410.
183. Birnbaum, J., Morris, Identification of a novel gene encoding an insulin responsive glucose transporter protein. Cell. 57 (1989), 305–315.
184. Cline, G.W., et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N. Engl. J. Med. 341 (1999), 240–246.
185. Rothman, D., et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 983–987.
186. Arya, A., Looi, C.Y., Cheah, S.C., et al. Anti-diabetic effects of Centratherum anthelminticum seeds methanolic fraction on pancreatic cells, β-TC6 and its alleviating role in type 2 diabetic rats. J. Ethnopharmacol. 144 (2012), 22–32.
187. Lee, H., Li, H., Noh, M., et al. Bavachin from Psoralea corylifolia improves insulin-dependent glucose uptake through insulin signaling and AMPK activation in 3T3-L1 adipocytes. Int. J. Mol. Sci., 17, 2016, 527.
188. Yang, X., Jing, Y., Chan, X., et al. Antidiabetic effects of flavonoids from Sophora flavescens, EtOAc extract in type 2 diabetic KK-ay mice. J. Ethnopharmacol. 171 (2015), 161–170.
189. Choi, S.I., Lee, H.A., Han, J.S., Gynura procumbens extract improves insulin sensitivity and suppresses hepatic gluconeogenesis in C57BL/KsJ-db/db mice. Nutr. Res. Pract. 10 (2016), 507–515.
190. Azevedo, M.F., Lima, C.F., Fernandes-Ferreira, M., Almeida, M.J., Wilson, J.M., Pereira-Wilson, C., Rosmarinic acid, major phenolic constituent of Greek sage herbal tea, modulates rat intestinal SGLT1 levels with effects on blood glucose. Mol. Nutr. Food Res. 55 (2011), S15–S25.
191. Jayanthy, G., Subramanian, S., Rosmarinic acid, a polyphenol, ameliorates hyperglycemia by regulating the key enzymes of carbohydrate metabolism in high fat diet-STZ induced experimental diabetes mellitus. Biomed Prev Nutr. 4 (2014), 431–437.
192. Farzadi, L., Khaki, A., Ghasemzadeh, A., Ouladsahebmadarek, E., Ghadamkheir, E., Effect of rosmarinic acid on sexual behavior in diabetic male rats. Afr. J. Pharm. Pharmacol 5 (2011), 1906–1910.
193. Tavafi, M., Ahmadvand, H., Khalatbari, A., Tamjidipoor, A., Rosmarinic acid ameliorates diabetic nephropathy in uninephrectomized diabetic rats. Iran J Basic Med Sci. 14 (2011), 275–283.
194. Jiang, W.L., Xu, Y., Zhang, S.P., Hou, J., Zhu, H.B., Effect of rosmarinic acid on experimental diabetic nephropathy. Basic Clin. Pharmacol. Toxicol. 110 (2012), 390–395.
195. Runtuwene, J., Cheng, K.C., Asakawa, A., Amitani, H., Amitani, M., Morinaga, A., et al. Rosmarinic acid ameliorates hyperglycemia and insulin sensitivity in diabetic rats, potentially by modulating the expression of pepck and glut4. Drug Design Development & Therapy. 10 (2016), 2193–2202.
196. Priscilla, D.H., Jayakumar, M., Thirumurugan, K., Flavanone naringenin: an effective antihyperglycemic and antihyperlipidemic nutraceutical agent on high fat diet fed streptozotocin induced type 2 diabetic rats. J. Funct. Foods 14 (2015), 363–373.
197. Mohler, M.L., He, Y., Wu, Z., Hwang, D.J., Miller, D.D., Recent and emerging anti-diabetes targets. Med. Res. Rev. 29 (2010), 125–195.
198. Al-Shaqha Waleed, M., Mohsin, Khan, Nasir, Salam, et al. Anti-diabetic potential of Catharanthus roseus Linn. and its effect on the glucose transport gene (GLUT-2 and GLUT-4) in streptozotocin induced diabetic wistar rats. BMC Complement Altern Med., 15, 2015, 379.
199. Zhu, C., Zhang, W., Mu, B., Zhang, F., Lai, N., Zhou, J., Xu, A., Liu, J., Li, Y., Effects of marine collagen peptides on glucose metabolism and insulin resistance in type 2 diabetic rats. J. Food Sci. Technol. 54 (2017), 2260–2269.
200. Rani, M.P., Krishna, M.S., Padmakumari, K.P., et al. Zingiber officinale extract exhibits antidiabetic potential via modulating glucose uptake, protein glycation and inhibiting adipocyte differentiation: an in vitro study. J. Sci. Food Agric. 92 (2012), 1948–1955.
201. Gujral, U.P., Narayan, K.M., Pradeepa, R.G., Deepa, M., Ali, M.K., Anjana, R.M., Kandula, N.R., Mohan, V., Kanaya, A.M., Comparing type 2 diabetes, prediabetes, and their associated risk factors in Asian Indians in India and in the U.S.: the CARRS and MASALA studies. Diabetes Care 38 (2015), 1312–1318.
202. Aronoff, S.L., Berkowitz, K., Shreiner, B., Want, L., Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 17 (2004), 183–190.
203. Huang, S., Czech, M.P., The GLUT4 glucose transporter. Cell Metab. 5 (2007), 237–252.
204. Hardie, D.G., Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. Proc. Nutr. Soc. 70 (2011), 92–99.
205. Koo, S.H., Flechner, L., Qi, L., Zhang, X., Screaton, R.A., Jeffrie, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., Takemori, H., Montminy, M., The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature., 437, 2005, 1109e1111.
206. Montminy, M., Cantley, L.C., The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 2005, 1642e1646.
207. Liao, J., Barthel, A., Nakatani, K., Roth, R.A., Activation of protein kinase B/Akt is sufficient to repress the glucocorticoid and cAMP induction of phosphoenolpyruvate carboxykinase gene. J. Biol. Chem., 273, 1998 (27320e27324).
208. Schmoll, D., Walker, K.S., Alessi, D.R., Grempler, R., Burchell, A., Guo, S., Walther, R., Unterman, T.G., Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR, Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J. Biol. Chem., 275, 2000 (36324e36333).
209. Yueh-Hsiung, K., Cheng-Hsiu, L., Chun-Ching, S., Dehydroeburicoic acid from Antrodia camphorata prevents the diabetic and dyslipidemic state via modulation of glucose transporter 4, peroxisome proliferator-activated receptor α expression and AMP-activated protein kinase phosphorylation in high-fat-fed mice. Int. J. Mol. Sci., 17, 2016, 872.
210. Wang, T., Jiang, H., Cao, S., Chen, Q., Cui, M., Wang, Z., et al. Baicalin and its metabolites suppresses gluconeogenesis through activation of ampk or AKT in insulin resistant HEPG-2 cells. Eur. J. Med. Chem. 141 (2017), 92–100.
211. Lee, H., Li, H., Jeong, J.H., Noh, M., Ryu, J.H., Kazinol B from Broussonetia kazinoki improves insulin sensitivity via AKT and AMPK activation in 3T3-L1 adipocytes. Fitoterapia. 112 (2016), 90–96.
212. Fauzi, F.M., John, C.M., Karunanidhi, A., Mussa, H.Y., Bender, A., Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies towards validating it as a long term therapy for type II diabetes. J. Ethnopharmacol. 197 (2017), 61–72.
213. Yu, S.H., Chen, S.Y.T., Li, W.S., Dubey, N.K., Chen, W.H., Chuu, J.J., et al. Hypoglycemic activity through a novel combination of fruiting body and mycelia of cordyceps militaris in high-fat diet-induced type 2 diabetes mellitus mice. J. Diabetes Res., 723190, 2015.
214. Lee, S.H., Ko, S.C., Kang, M.C., Lee, D.H., Jeon, Y.J., Octaphlorethol A, a marine algae product, exhibits antidiabetic effects in type 2 diabetic mice by activating amp-activated protein kinase and upregulating the expression of glucose transporter 4. Food Chem. Toxicol. 91 (2016), 58–64.
215. Zhu, K.X., Nie, S.P., Tan, L.H., Li, C., Gong, D.M., Xie, M.Y., A polysaccharide from Ganoderma atrum improves liver function in type 2 diabetic rats via antioxidant action and short-chain fatty acids excretion. J. Agric. Food Chem. 64 (2016), 1938–1944.
216. Wang, J., Huang, Y., Li, K., Chen, Y., Vanegas, D., Mclamore, E.S., et al. Leaf extract from Lithocarpus polystachyus Rehd. Promote glycogen synthesis in T2DM mice. Plos One, 11, 2016, e0166557.
217. Yan, F., Dai, G., Zheng, X., Mulberry anthocyanin extract ameliorates insulin resistance by regulating PI3K/AKT pathway in HEPG2 cells and db/db mice. J. Nutr. Biochem. 36 (2016), 68–80.
218. Yang, J.Y., Moon, E., Nam, S.H., Friedman, M., Antidiabetic effects of rice hull smoke extract on glucose-regulating mechanism in type 2 diabetic mice. J. Agric. Food Chem. 60 (2012), 7442–7449.
219. Cheon, J.M., Kim, D.I., Kim, K.S., Insulin sensitivity improvement of fermented Korean Red Ginseng (Panax ginseng) mediated by insulin resistance hallmarks in old-aged ob/ob mice. J. Ginseng Res. 39 (2015), 331–337.
220. Lu, J.M., Wang, Y.F., Yan, H.L., Lin, P., Gu, W., Yu, J., Antidiabetic effect of total saponins from Polygonatum kingianum in streptozotocin-induced daibetic rats. J. Ethnopharmacol. 179 (2016), 291–300.
221. Hsu, F.L., Huang, C.F., Chen, Y.W., Yen, Y.P., Wu, C.T., Uang, B.J., et al. Antidiabetic effects of pterosin a, a small-molecular-weight natural product, on diabetic mouse models. Diabetes. 62 (2013), 628–638.
222. Elyasiyan, U., Nudel, A., Skalka, N., Rozenberg, K., Drori, E., Oppenheimer, R., et al. Anti-diabetic activity of aerial parts of Sarcopoterium spinosum. BMC Complement. Altern. Med., 17, 2017, 356.
223. Zhao, P., Alam, M.B., Lee, S.H., Kim, Y.J., Lee, S., An, H., et al. Spatholobus suberectus exhibits antidiabetic activity in vitro and in vivo through activation of AKT-AMPK pathway. Evid. Based Complement. Alternat. Med., 6091923, 2017.
224. Gosch, C., Halbwirth, H., Stich, K., Phloridzin: biosynthesis, distribution and physiological relevance in plants. Phytochemistry 71 (2010), 838–843.
225. Han, L., Fang, C., Zhu, R., Peng, Q., Li, D., Wang, M., Inhibitory effect of phloretin on α-glucosidase: kinetics, interaction mechanism and molecular docking. Int. J. Biol. Macromol. 95 (2017), 520–527.
226. Najafian, M., Jahromi, M.Z., Nowroznejhad, M.J., Khajeaian, P., Kargar, M.M., Sadeghi, M., et al. Phloridzin reduces blood glucose levels and improves lipids metabolism in streptozotocin-induced diabetic rats. Mol. Biol. Rep. 39 (2012), 5299–5306.
227. Masumoto, S., Akimoto, Y., Oike, H., Kobori, M., Dietary phloridzin reduces blood glucose levels and reverses SGLT1 expression in the small intestine in streptozotocin-induced diabetic mice. J. Agric. Food Chem. 57 (2009), 4651–4656.
228. Sakuma, S., Sagawa, T., Masaoka, Y., et al. Stabilization of enzyme-susceptible glucoside bonds of phloridzin through conjugation with poly (γ-glutamic acid). J. Control. Release 133 (2009), 125–131.
229. + glucose cotransporter (SGLT1) in the small intestine. J. Control. Release 125 (2008), 42–49.
230. Shao, X., Bai, N., He, K., Ho, C.T., Yang, C.S., Sang, S., Apple polyphenols, phloretin and phloridzin: new trapping agents of reactive dicarbonyl species. Chem. Res. Toxicol. 21 (2008), 2042–2050.
231. Dewanjee, S., Das, A.K., Sahu, R., Gangopadhyay, M., Antidiabetic activity of Diospyros peregrine fruit: effect on hyperglycemia, hyperlipidemia and augmented oxidative stress in experimental type 2 diabetes. Food Chem. Toxicol. 47 (2009), 2679–2685.
232. Ananthan, R., Latha, M., Ramkumar, K.M., Pari, L., Baskar, C., Narmatha Bai, V., Modulatory effects of Gymnema montanum leaf extraction alloxan induced oxidative stress in wistar rats. Nutrition. 20 (2004), 280–285.
233. Ahmed, D., Kumar, V., Verma, A., Gupta, P.S., Kumar, H., Dhingra, V., et al. Antidiabetic, renal/hepatic/pancreas/cardiac protective and antioxidant potential of methanol/dichloromethane extract of Albizzia lebbeck benth. stem bark (alex) on streptozotocin induced diabetic rats. BMC Complement. Altern. Med., 14, 2014, 243.
234. Zhang, J.G., Liu, Q., Liu, Z.L., Li, L., Yi, L.T., Antihyperglycemic activity of anoectochilus roxburghii, polysaccharose in diabetic mice induced by high-fat diet and streptozotocin. J. Ethnopharmacol. 164 (2015), 180–185.
235. Liu, Y., Sun, J., Rao, S., Su, Y., Yang, Y., Antihyperglycemic, antihyperlipidemic and antioxidant activities of polysaccharides from Catathelasma ventricosum in streptozotocin-induced diabetic mice. Food Chem. Toxicol. 57 (2013), 39–45.
236. Asgary, S., Rafieiankopaei, M., Shamsi, F., Najafi, S., Sahebkar, A., Biochemical and histopathological study of the anti-hyperglycemic and anti-hyperlipidemic effects of cornelian cherry (Cornus mas L.) in alloxan-induced diabetic rats. J. Complement. Integr. Med., 11, 2014, 63.
237. Taher, Muhammad, Tg Zakaria, Tg Muhamad Faris Syafiq, Susanti, Deny, Zakaria, Zainul Amiruddin, Hypoglycaemic activity of ethanolic extract of Garcinia mangostana Linn. in normoglycaemic and streptozotocin-induced diabetic rats. BMC Complement. Altern. Med., 16, 2016, 135.
238. Kumar, V., Ahmed, D., Gupta, P.S., Anwar, F., Mujeeb, M., Anti-diabetic, anti-oxidant and anti-hyperlipidemic activities of melastoma malabathricum Linn. leaves in streptozotocin induced diabetic rats. BMC Complement. Altern. Med., 13, 2013, 222.
239. Ma, Q., Guo, Y., Sun, L., Zhuang, Y., Anti-diabetic effects of phenolic extract from rambutan peels (Nephelium lappaceum) in high-fat diet and streptozotocin induced diabetic mice. Nutrients, 9, 2017.
240. Krishnasamy, G., Muthusamy, K., Chellappan, D.R., Subbiah, N., Antidiabetic, antihyperlipidaemic, and antioxidant activity of Syzygium densiflorum fruits in streptozotocin and nicotinamide-induced diabetic rats. Pharm. Biol., 2, 2015, 1.
241. Moodley, K., Joseph, K., Naidoo, Y., Islam, S., Mackraj, I., Antioxidant, antidiabetic and hypolipidemic effects of Tulbaghia violacea harv. (wild garlic) rhizome methanolic extract in a diabetic rat model. BMC Complement. Altern. Med., 15, 2015, 408.
242. Emordi, J.E., Agbaje, E.O., Oreagba, I.A., Iribhogbe, O.I., Antidiabetic and hypolipidemic activities of hydroethanolic root extract of Uvaria chamae in streptozotocin induced diabetic albino rats. BMC Complement. Altern. Med., 16, 2016, 468.
243. Kumar, V., Ahmed, D., Verma, A., et al. Umbelliferone β-D-galactopyranoside from Aegle marmelos (L.) corr. an ethnomedicinal plant with antidiabetic, antihyperlipidemic and antioxidative activity. BMC Complement. Altern. Med., 13, 2013, 273.
244. Kumar, V., Anwar, F., Ahmed, D., Verma, A., Ahmed, A., Damanhouri, Z.A., et al. Paederia foetida Linn. leaf extract: an antihyperlipidemic, antihyperglycaemic and antioxidant activity. BMC Complement. Altern. Med., 14, 2014, 76.
245. Jung, U.J., Yong, B.P., Sang, R.K., Choi, M.S., Supplementation of persimmon leaf ameliorates hyperglycemia, dyslipidemia and hepatic fat accumulation in type 2 diabetic mice. PLoS One 7 (2012), 822–824.
246. Lin, H.V., Tsou, Y.C., Chen, Y.T., Lu, W.J., Hwang, P.A., Effects of low-molecular-weight fucoidan and high stability fucoxanthin on glucose homeostasis, lipid metabolism, and liver function in a mouse model of type II diabetes. Mar. Drugs, 15, 2017, 113.
247. Irudayaraj, S.S., Sunil, C., Duraipandiyan, V., Ignacimuthu, S., Antidiabetic and antioxidant activities of toddalia asiatica (L.) lam. leaves in streptozotocin induced diabetic rats. J. Ethnopharmacol., 143, 2012.
248. Adefegha, S.A., Oboh, G., Adefegha, O.M., Boligon, A.A., Athayde, M.L., Antihyperglycemic, hypolipidemic, hepatoprotective and antioxidative effects of dietary clove (Szyzgium aromaticum) bud powder in a high-fat diet/streptozotocin-induced diabetes rat model. J. Sci. Food Agric. 94 (2014), 2726–2737.
249. Hotamisligil, G.S., Johnson, R.S., Distel, R.J., Ellis, R., Papaioannou, V.E., Spiegelman, B.M., Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274 (1996), 1377–1379.
250. Uysal, K.T., Wiesbrock, S.M., Marino, M.W., Hotamisligil, G.S., Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389 (1997), 610–614.
251. Mohamed-Ali, V., Goodrick, S., Rawesh, A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α in vivo. J. Clin. Endocrinol. Metab. 82 (1997), 4196–4200.
252. Willett, W., Nutritional epidemiology. Annu. Rev. Gerontol. Geriatr., 15, 1998.
253. Wang, K., Cao, P., Shui, W., et al. Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. Food Funct. 6 (2015), 902–909.
254. Chen, F., Xiong, H., Wang, J., Ding, X., Shu, G., Mei, Z., Antidiabetic effect of total flavonoids from Sanguis draxonis in type 2 diabetic rats. J. Ethnopharmacol. 149 (2013), 729–736.
255. Ananda, P.K., Kumarappan, C., Sunil, C., Kalaichelvan, V., Effect of biophytum sensitivum on streptozotocin and nicotinamide-induced diabetic rats. Asian Pac. J. Trop. Biomed. 2 (2012), 31–35.
256. Siqueira, J.T., Batistela, E., Pereira, M.P., Silva, V.C.D., Junior, P.T.D.S., Kawashita, N.H., et al. Combretum lanceolatum flowers ethanol extract inhibits hepatic gluconeogenesis: an in vivo mechanism study. Pharm. Biol. 54 (2016), 1671–1679.
257. Yoshitomi, H., Tsuru, R., Li, L., Zhou, J., Kudo, M., Liu, T., et al. Cyclocarya paliurus extract activates insulin signaling via sirtuin1 in C2C12 myotubes and decreases blood glucose level in mice with impaired insulin secretion. PLoS One, 12, 2017, e0183988.
258. Alzuaidy, M.H., Mumtaz, M.W., Hamid, A.A., Ismail, A., Mohamed, S., Razis, A.F.A., Biochemical characterization and 1 H NMR based metabolomics revealed melicope lunu-ankenda leaf extract a potent anti-diabetic agent in rats. BMC Complement. Altern. Med., 17, 2017, 359.
259. Okolo, C.A., Ejere, V.C., Chukwuka, C.O., Ezeigbo, I.I., Nwibo, D.D., Okorie, A.N., Hexane extract of Dacryodes edulis fruits possesses anti-diabetic and hypolipidaemic potentials in alloxan diabetes of rats. Afr. J. Tradit. Complement. Altern. Med. 13 (2016), 132–144.
260. Shalaby, N.M., Abdalla, H.I., Aly, H.F., Albalawy, M.A., Shaker, K.H., Bouajila, J., Preliminary in vitro and in vivo evaluation of antidiabetic activity of Ducrosia anethifolia boiss. and its linear furanocoumarins. Biomed. Res. Int., 2014, 480545.
261. Shih, C.C., Ciou, J.L., Lin, C.H., Wu, J.B., Ho, H.Y., Cell suspension culture of Eriobotrya japonica regulates the diabetic and hyperlipidemic signs of high-fat-fed mice. Molecules 18 (2013), 2726–2753.
262. Guo, X., Yoshitomi, H., Gao, M., Qin, L., Duan, Y., Sun, W., et al. Guava leaf extracts promote glucose metabolism in SHRSP.Z-leprfa/izm rats by improving insulin resistance in skeletal muscle. BMC Complement. Altern. Med., 13, 2013, 52.
263. Nabi, S.A., Kasetti, R.B., Sirasanagandla, S., Tilak, T.K., Rao, C.A., Antidiabetic and antihyperlipidemic activity of piper longum, root aqueous extract in STZ induced diabetic rats. BMC Complement. Altern. Med., 13, 2013, 37.
264. Dong, J.S., Hwang, S.Y., Kim, M.H., et al. Anti-diabetic and hepato-renal protective effects of Ziyuglycoside II methyl ester in type 2 diabetic mice. Nutrients 7 (2015), 5469–5483.
265. Liu, W., Zheng, Y., Zhang, Z., Yao, W., Gao, X., Hypoglycemic, hypolipidemic and antioxidant effects of Sarcandra glabra polysaccharide in type 2 diabetic mice. Food Funct., 5, 2014, 2850.
266. Pallavi, M., Suresh, K., Manjiri, K., Vijaya, P., Prabhakar, R., Aniket, K., et al. Antidiabetic, lipid normalizing, and nephroprotective actions of the strawberry: a potent supplementary fruit. Int. J. Mol. Sci., 18, 2017, 124.
267. Shukla, K., Dikshit, P., Shukla, R., Gambhir, J.K., The aqueous extract of withania coagulans fruit partially reverses nicotinamide/streptozotocin-induced diabetes mellitus in rats. J. Med. Food, 15, 2012, 718.
268. Nwanjo, H.U., Efficacy of aqueous leaf extract of vernonia amygdalina on plasma lipoprotein and oxidative status in diabetic rat models. Niger. J. Physiol. Sci., 20, 2005, 39.
269. World Health Organization (WHO) Global Report on Diabetes. http://www.who.int/iris/bitstream/10665 (2016).
270. Mukai, N., Doi, Y., Ninomiya, T., Hirakawa, Y., Nagata, M., Yoshida, D., et al. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama study. J. Diabetes Investig. 5 (2014), 162–169.
271. Wise, J., A third of adults in England have prediabetes, study says. BMJ., 348, 2014, g3791.
272. Mota, M., Popa, S.G., Mota, E., Mitrea, A., Catrinoiu, D., Cheta, D.M., et al. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. Journal of Diabetes. 8 (2016), 336–344.
273. Yin, M.C., Lin, M.C., Mong, M.C., Lin, C.Y., Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice. J. Agric. Food Chem. 60 (2012), 7697–7701.
274. Jiang, Q., Yang, X., Du, P., He, Z., Zhang, T., Dual strategies to improve oral bioavailability of oleanolic acid: enhancing water-solubility, permeability and inhibiting cytochrome p450 isozymes. Eur. J. Pharm. Biopharm. 99 (2015), 65–72.
275. Li, F., Li, Y., Li, Q., Shi, X., Guo, Y., Acute and subacute oral toxicity evaluation of Eriobotrya japonica leaf triterpene acids in icr mice. Evid. Based Complement. Alternat. Med. 2017 (2017), 1–9.
276. Ivorra, M., Paya, M., Villar, A., Hypoglycemic and insulin release effects of tormentic acid: a new hypoglycemic natural product. Planta Med. 54 (1988), 282–286.
277. Sánchez-González, M., Lozano, M.G., Juan, M.E., Planas, J.M., Assessment of the safety of maslinic acid, a bioactive compound from\r, o\r, lea europaea\r, l. Mol. Nutr. Food Res. 57 (2013), 339–346.
278. Veeresham, Ciddi, Natural products derived from plants as a source of drugs. J. Adv. Pharm. Technol. Res., 3, 2012, 200.
279. Karunanayake, E.H., Tennekoon, K.H., Search of novel hypoglycaemic agents from medicinal plants. Sharma, A.K., (eds.) Diabetes Mellitus and its Complications. An Update, 1993, Macmillan India Ltd, New Delhi.
280. Ribnicky, D.M., Kuhn, P., Poulev, A., Logendra, S., Zuberi, A., Cefalu, W.T., Raskin, I., Improved absorption and bioactivity of active compounds from an anti-diabetic extract of Artemisia dracunculus l. Int. J. Pharm. 370 (2009), 87–92.
281. Patel, D.K., Kumar, R., Laloo, D., Hemalatha, S., Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity. Asian Pac. J. Trop. Biomed. 2 (2012), 411–420.
282. Bunel, V., Ouedraogo, M., Nguyen, A., Stévigny, C., Duez, P., Methods applied to the in vitro primary toxicology testing of natural products: state of the art, strengths, and limits. Planta Med. 80 (2014), 1210–1226.
283. Nunes, T., Almeida, L., Rocha, J.F., Falcão, A., et al. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol. 49 (2009), 1477–1482.
284. Walle, T., Hsieh, F., Delegge, M.H., Jr, O.J., Walle, U.K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 32, 2004, 1377.
285. Chen, W., Miao, Y.Q., Fan, D.J., Yang, S.S., Lin, X., Meng, L.K., et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech 12 (2011), 705–711.
286. Ader, P., Wessmann, A., Wolffram, S., Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic. Biol. Med. 28 (2000), 1056–1067.
287. Berger, L.M., Wein, S., Blank, R., Metges, C.C., Wolffram, S., Bioavailability of the flavonol quercetin in cows after intraruminal application of quercetin aglycone and rutin. J. Dairy Sci. 95 (2012), 5047–5055.